Cancer Biological Therapy Market Research Report- EMEA Forecast To 2027

EMEA Cancer Biological Therapy Market information, by type (monoclonal antibodies, interferons, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others) by end users (hospitals & clinics, cancer research centers, laboratories) - Forecast to 2027

ID: MRFR/Pharma/0173-CR | April 2017 | Region: Global | 85 pages

Europe, the Middle East, and Africa Cancer Biological Therapy Market Overview:


The EMEA Cancer biological therapy market Research forecasts a CAGR of XX% by the year 2021. Cancer is ranked the world’s second most lethal disease caused due to abnormal cell growth that spreads across the human body. Most of the vital and visible signs of cancer are hair loss, weight loss, bleeding in internal organs, benign tumors, lumps in the body, and changes in digestion, and improper bowel movement. There are more than 100 types of cancer known to humans. Major causes of cancer in humans are excessive use of tobacco, no or minimal physical activity, high sugar intake, excessive smoking and drinking, high junk food intake, and other infections like hepatitis B and C.


Most individuals inherit cancer is caused because of mutation of genes. Stage and type of cancer are the deciding factors if the patient could survive the illness or not. Proper screening, ration therapy, chemotherapy, surgery, and maintaining a proper lifestyle are the only start of cancer treatment. Progressive screening and treatment and clearer PET scans give a cancer patient an ideal life survival up to 10 years of the first sign of cancer. The overall health of the patient is degraded to a greater extent. Many healthcare centers have invested in cancer clinics and hospitals to develop hypotheses and models to have a better understanding of the disease. It is reported by WHO that more than 18 million new cancer cases are registered annually with an investment of more than 1.6 trillion US dollars per year.


COVID-19 Analysis:


The global prevalence of COVID-19 since the November of 2019 has held down the world economically, socially, and politically. The world suffered major losses in terms of manpower, local business, corporates, etc. The countries around the globe went into complete lockdown to contain the virus in local areas. Travel and communication were completely restricted due to the fear of the virus and the effect and cure unknown to mankind. People suffering from cancer had adverse effects and, in few cases, it led to life loss. The government, charity, and private funds which were the source of cancer research were depleted due to loss in business and limited money to globally feed the public during the pandemic. Although the study in cancer research did not come to a stand-still any new venture was not made during the time of the pandemic. Slowly, as the world is coming back on its feet, healthcare centers have seen a rise in public and private investors to aid the study and research of cancer.


Europe, the Middle East, and Africa Cancer Biological Therapy Market Dynamics:


Drivers:


With more than 18 million new cancer cases are registered annually with an investment of more than 1.6 trillion US dollars per year as recorded in 2016, the EMEA Cancer biological therapy market has seen a high in research and development area in recent years. The healthcare centers around the world have come up with patient assistance programs (PAPs) with the government’s health to create awareness about the type and stages of cancer. With more than 15% of children under cancer, radar has healthcare centers across the world invest more in NICU cancer departments. There are more than 100 types of cancer known to mankind but few of the major cancers include lung, breast, blood, gastric, colorectal, esophageal, and pancreatic which not only affect the major organs but also decrease the lifespan of humans.


Opportunities:


The Europe, the Middle East, and Africa cancer biological therapy market is all set to witness growth because of the rising cancer incidences among the geriatric populations on a global level. People who are aged above 50 years are more vulnerable and have high chances of developing cancer cells in the body. The statistics released by the World Cancer Research Fund show that by the beginning of the forecast year of 2018, there were approximately 18 million cases of cancer from different corners of the globe. By the end of the same forecast year, there was a 12.3% growth in the cases, worldwide.


The biological therapies and techniques used help in enhancing the immune system and help in the development of better technologies that are playing a major role in helping people to recover at a fast rate. The market is expected to cross a market valuation of USD 108 billion, by the end of the future forecast year of 2024, as published in the Global Market Insights Inc. report.


Technology Analysis:


Cancer biological therapy is rapidly growing due to a greater number of investors interested in funding the research and development department of cancer therapy. Cancer biological therapy deals with injecting drugs in humans on cancer-infected areas to decrease the growth of the tumor or performing radiation-based therapy to the infected areas to diminish the growth. In certain cancers like breast cancer, lung cancer, gynecologic cancer, etc. infected body parts can also be cut out as it is a proven fact that cancer doesn’t eventually get cured it needs to be treated time again depending on the progression and regular PET scans results. Cancer biological therapy around the world has been studied to analyze the cancer type and factors leading to its growth. This analysis had led the government and private sectors to study the market-growth in cancer study and invest accordingly.


Segment Overview:


By Type:


EMEA Cancer biological therapy market is segmented by type as the different type of cancers known to humans like breast cancer, lungs cancer, blood cancer, prostate cancer, gastric cancer, colorectal cancer, esophageal cancer, pancreatic cancer, etc. and the different type of therapies used to treat them depending on stage and type like targeted therapy, radiation, cancer growth inhibitors, antibodies, interleukins, vaccines, interferons, colony-stimulating factors and treatments, gene therapy, etc.


By Vertical:


EMEA Cancer biological therapy market is segmented by vertical as medical centers, clinical trial hospitals, and healthcare centers, laboratories, and cancer-related research and development centers. Few of these centers are funded by the government and the others by private investors depending on the revenue and growth of these centers.


Regional Analysis:


North America is the current leader of the world’s cancer therapy market due to the high investments done in the research and development center of the cancer department leading to the adaption of cancer therapies. Europe is dominant in the EMEA region of the EMEA Cancer biological therapy market with an expectation of a market rise to more than 20,000 million US dollars by the year 2021. The European EMEA region market of EMEA Cancer biological therapy market Research forecasts a CAGR of 5.2% by the year 2021. Asia-Pacific countries like China, Japan, and India have also contributed to the increasing Cancer biological therapy industry and are estimated to continue to grow in upcoming years. Middle East (Oman, Kuwait, UAE, Qatar, Bahrain, and Saudi Arabia) is likely to see a CAGR of 4.3% by 2021 with an estimated revenue of more than 6000 million US dollars.


Competitive Landscape:


The EMEA Cancer biological therapy market is on the global rise due to an alarming rate at which cancer patients are increasing. To be prepared and composed for this increasing number of patients is on the priority of many healthcare departments overall the globe. Public and private sectors have been funded seeing to the expansion of cancer patients and related centers for it. Few of the key market players in the EMEA Cancer biological therapy market are Bayer AG, Novartis AG, Johnson and Johnson, Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc., AstraZeneca plc., Celgene Corporation, Engeneic Ltd., Eli Lily and Company, Merck and Co., Hoffmann-La Roche Ag., Teva Pharmaceutical, and many more.


Recent Developments:


In January 2020, a biopharmaceutical company called ArQule Inc joined hands with Merck and Co. to study the growth and development of a device for kinase inhibitor to treat cancer patients. AVEO Oncology was successful in getting FDA approval and clearance in June 2020, for the discovery and development of a new drug tivozanib for refractory renal cell disruption and carcinoma. Glaxo Smith Kline PLC joined hands with TESARO Inc. in the January of 2019 to pipeline and expand the study of oncology and see if it fits to provide commercial revenue to the EMEA Cancer biological therapy market.


Report Overview:


The EMEA Cancer biological therapy market provides a statistical and logical analysis of the market growth and the factors leading to it. The report also addresses the opportunities leading to an increasing EMEA Cancer biological therapy market by analyzing the supply chain from public and private sectors and the developments made by the R&D department in the cancer region. Globally speaking North America, Europe, China, Japan, and the Middle East are highly invested in the EMEA Cancer biological therapy market to maintain the growth of the world’s healthcare center. The report provides a brief insight into the strategic alliances between the public and private sectors for the cancer biological therapy industry.



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


Europe, the Middle East, and Africa Cancer Biological Therapy Market is projected to grow at XX CAGR during the forecast period.

Different end use industries of EMEA cancer biological therapy include laboratories, cancer research centers, and hospitals & clinics.

Europe is predicted to dominate the EMEA Cancer Biological Therapy Market.

Monoclonal antibodies will dominate the EMEA Cancer Biological Therapy Market.

1 Report Prologue

2 INTRODUCTION

2.1 definition

2.2 Scope of Study:

2.2.1 Research Objective

2.3 MARKET STRUCTURE

3 Research Process:

3.1 Primary Research:

3.2 Secondary Research:

3.3 top-down & bottom-up approach:

4 MARKET DYNAMICS

4.1 DRIVERS

4.1.1 Increasing Cancer Survival Rate

4.1.2 Growing demand for advanced therapies

4.1.3 Less number of side effects as compared to conventional treatment methods

4.1.4 Growth of cancer healthcare facilities in emerging countries 16

4.1.5 chainging lifestyle and increasing smoking population in middle east & africa

4.2 RESTRAINTS

4.2.1 High cost of Cancer biological therapy

4.3 Opportunities

4.3.1 UnTapped types of Cancers

4.4 MACROECONOMIC INDICATORS

5 EMEA Cancer biological therapy, by phases

5.1 Introduction

5.2 Phases

6 EMEA Cancer Biological Therapy Market, BY Type

6.1 key findings

6.2 Monoclonal Antibodies

6.3 Interferons

6.4 Interleukins

6.5 Cancer growth inhibitors

6.6 Gene Therapy

6.7 Colony-Stimulating Factors

6.8 Targeted Therapy

6.9 CANCER VACCINES

7 EMEA Cancer Biological Therapy market, by end-users

7.1 key findings

7.2 Introduction

7.3 Hospitals & Clinics

7.4 Cancer Research Centers

7.5 Laboratories

8 EMEA Cancer Biological Therapy, by Region

8.1 key findings

EMEA Cancer biological therapy, by phases

EMEA Cancer Biological Therapy Market, BY Type

EMEA Cancer Biological Therapy market, by end-users

EMEA Cancer Biological Therapy Market, By Company

8.2 Europe 31

EMEA Cancer biological therapy, by phases

EMEA Cancer Biological Therapy Market, BY Type

EMEA Cancer Biological Therapy market, by end-users

EMEA Cancer Biological Therapy Market, By Company

8.3 Middle East & Africa

EMEA Cancer biological therapy, by phases

EMEA Cancer Biological Therapy Market, BY Type

EMEA Cancer Biological Therapy market, by end-users

EMEA Cancer Biological Therapy Market, By Company

9 Competitive landscape

9.1 Market Share Analysis

10 EMEA Cancer Biological Therapy Market, By Company

10.1 Amgen Inc.

10.1.1 Overview

10.1.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.1.3 FINANCIAL UPDATES

10.1.4 KEY DEVELOPMENTS

10.2 Bristol-Myers Squibb

10.2.1 Overview

10.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.2.3 FINANCIAL UPDATES

10.2.4 KEY DEVELOPMENTS

10.3 Celgene Corporation

10.3.1 Overview

10.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.3.3 FINANCIAL UPDATES

10.3.4 KEY DEVELOPMENTS

10.4 ELI Lilly and Company

10.4.1 Overview

10.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.4.3 FINANCIAL UPDATES

10.4.4 KEY DEVELOPMENTS

10.5 EnGeneIC Ltd

10.5.1 Overview

10.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.5.3 Financials UPDATES

10.5.4 Key Developments

10.6 F. Hoffmann-La Roche AG

10.6.1 Overview

10.6.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.6.3 FINANCIAL UPDATES

10.6.4 KEY DEVELOPMENTS

10.7 Merck & Co., Inc.

10.7.1 Overview

10.7.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.7.3 FINANCIAL UPDATES

10.7.4 KEY DEVELOPMENTS

10.8 Novartis

10.8.1 Overview

10.8.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.8.3 FINANCIAL UPDATES

10.8.4 KEY DEVELOPMENTS

10.9 pfizer Inc.

10.9.1 Overview

10.9.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.9.3 FINANCIAL UPDATES

10.9.4 KEY DEVELOPMENTS

10.10 Seattle Genetics, Inc.

10.10.1 Overview

10.10.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.10.3 FINANCIAL UPDATES

10.10.4 key developments

10.11 Teva Pharmaceutical Industries Ltd

10.11.1 Overview

10.11.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

10.11.3 Financials

10.11.4 Key Developments


11 List of Tables

TABLE 1 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION) 23

TABLE 2 MONOCLONAL ANTIBODIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION) 24

TABLE 3 INTERFERONS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 25

TABLE 4 INTERLEUKINS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 26

TABLE 5 CANCER GROWTH INHIBITORS FOR CANCER BIOLOGIC THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 27

TABLE 6 GENE THERAPY FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 28

TABLE 7 COLONY STIMULATING FACTOR FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 29

TABLE 8 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY END USER, 2020-2027 (USD MILLION) 31

TABLE 9 HOSPITALS & CLINICS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 31

TABLE 10 CANCER RESEARCH CENTERS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 32

TABLE 11 LABORATORIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 33

TABLE 12 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 35

TABLE 13 NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2020-2027 (USD MILLION) 37

TABLE 14 NORTH AMERICA BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 38

TABLE 15 NORTH AMERICA BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 39

TABLE 16 U.S. CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 40

TABLE 17 U.S. CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 41

TABLE 18 CANADA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 42

TABLE 19 CANADA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 43

TABLE 20 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2020-2027 (USD MILLION) 45

TABLE 21 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 46

TABLE 22 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 47

TABLE 23 GERMANY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 48

TABLE 24 GERMANY CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 49

TABLE 25 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 50

TABLE 26 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 51

TABLE 27 U.K. CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 52

TABLE 28 U.K. CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 53

TABLE 29 ITALY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 54

TABLE 30 ITALY CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 55

TABLE 31 SPAIN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 56

TABLE 32 SPAIN CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 57

TABLE 33 ROE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 58

TABLE 34 ROE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 59

TABLE 35 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2020-2027 (USD MILLION) 61

TABLE 36 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 62

TABLE 37 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 63

TABLE 38 JAPAN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 64

TABLE 39 JAPAN CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 65

TABLE 40 CHINA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 66

TABLE 41 CHINA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 67

TABLE 42 INDIA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 68

TABLE 43 INDIA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 69

TABLE 44 REPUBLIC OF KOREA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 70

TABLE 45 REPUBLIC OF KOREA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 71

TABLE 46 ROA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 72

TABLE 47 ROA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 73

TABLE 48 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 74

TABLE 49 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 75

TABLE 50 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 76

TABLE 51 MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 80

TABLE 52 MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 81

TABLE 53 AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 82

TABLE 54 AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 83

TABLE 55 AMGEN INC.: KEY DEVELOPMENT 87

12 List of Figures

FIGURE 1 RESEARCH PROCESS 14

FIGURE 2 MARKET DYNAMICS FOR GLOBAL CANCER BIOLOGICAL THERAPY MARKET 16

FIGURE 3 ATTRITION RATE OF PHASE III CLINICAL TRIALS IN EUROPE, 2020 (%) 20

FIGURE 4 CANCER BIOLOGICAL THERAPY SUCCESS RATES IN VARIOUS PHASES OF CLINICAL TRIALS 21

FIGURE 5 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY TYPE 2020 22

FIGURE 6 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY END USER, 2020 30

FIGURE 7 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY REGION, 2020 34

FIGURE 8 NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2020 37

FIGURE 9 EUROPE CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2020 45

FIGURE 10 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2020 61

FIGURE 11 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2020 73

FIGURE 12 QATAR: CANCER INCIDENCE AND MORTALITY RATES (%) 77

FIGURE 13 UAE: CANCER INCIDENCE AND MORTALITY RATES (%) 77

FIGURE 14 KUWAIT: CANCER INCIDENCE AND MORTALITY RATES (%) 78

FIGURE 15 BAHRAIN: CANCER INCIDENCE AND MORTALITY RATES (%) 78

FIGURE 16 OMAN: CANCER INCIDENCE AND MORTALITY RATES (%) 79

FIGURE 17 SAUDI ARABIA: CANCER INCIDENCE AND MORTALITY RATES (%) 79

FIGURE 18 GLOBAL CANCER BIOLOGICAL THERAPY MARKET: COMPANY SHARE ANALYSIS, 2020 (%) 84

FIGURE 19 AMGEN INC.: KEY FINANCIALS 86

FIGURE 20 AMGEN INC.: SEGMENTAL REVENUE 86

FIGURE 21 AMGEN INC.: GEOGRAPHICAL REVENUE 87

FIGURE 22 BRISTOL-MYERS SQUIBB.: KEY FINANCIALS 89

FIGURE 23 BRISTOL-MYERS SQUIBB.: SEGMENTAL REVENUE 89

FIGURE 24 BRISTOL-MYERS SQUIBB: GEOGRAPHICAL REVENUE 90

FIGURE 25 CELGENE CORPORATION.: KEY FINANCIALS 92

FIGURE 26 CELGENE CORPORATION.: SEGMENTAL REVENUE 92

FIGURE 27 CELGENE CORPORATION: GEOGRAPHICAL REVENUE 93

FIGURE 28 ELI LILLY AND COMPANY.: KEY FINANCIALS 95

FIGURE 29 ELI LILLY AND COMPANY.: SEGMENTAL REVENUE 95

FIGURE 30 ELI LILLY AND COMPANY: GEOGRAPHICAL REVENUE 96

FIGURE 31 F. HOFFMANN-LA ROCHE AG: FINANCIAL REVENUE 99

FIGURE 32 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE 99

FIGURE 33 F. HOFFMANN-LA ROCHE AG: GEOGRPAHICAL REVENUE 100

FIGURE 34 MERCK & CO., INC: FINANCIAL REVENUE 102

FIGURE 35 MERCK & CO., INC: SEGMENTAL REVENUE 102

FIGURE 36 MERCK & CO., INC: GEOGRPAHICAL REVENUE 103

FIGURE 37 NOVARTIS: FINANCIAL REVENUE 105

FIGURE 38 NOVARTIS: SEGMENTAL REVENUE 105

FIGURE 39 NOVARTIS: GEOGRPAHICAL REVENUE 106

FIGURE 40 PFIZER INC: FINANCIAL REVENUE 108

FIGURE 41 PFIZER INC: SEGMENTAL REVENUE 108

FIGURE 42 PFIZER INC: GEOGRPAHICAL REVENUE 109